# Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

> **NCT05710367** · PHASE2 · UNKNOWN · sponsor: **Albina Nowak, MD** · enrollment: 46 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05710367
- **Lead sponsor:** Albina Nowak, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710367, "Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05710367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*